The Future Of Nano Technology
- Alan Watts
- Anti-Aging Medicine
- David Sinclair
- Gene Medicine
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Hormone Replacement Therapy
- Human Genetic Engineering
- Human Reproduction
- Integrative Medicine
- Life Skills
- Longevity Medicine
- Machine Learning
- Medical School
- Nano Medicine
- Parkinson's disease
- Quantum Computing
- Regenerative Medicine
- Stem Cell Therapy
- Stem Cells
- Researchers combine immunotherapy with nano-particles to kill cancer cells – The Brussels Times
- New Approaches in Breast Cancer Therapy Through Green Nanotechnology a | IJN – Dove Medical Press
- Complete Overview of Cancer Nanomedicine Market to Witness High Rate of Growth in Forthcoming Years – Fusion Science Academy
- Controlled phage therapy hints at future alternative to antibiotics – New Atlas
- Healthcare IT Market trends research and projections – GroundAlerts.com
|Search Immortality Topics:|
Category Archives: Biotechnology
Ross Murdoch has been the CEO of Avecho Biotechnology Limited (ASX:AVE) since 2015. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels.
Check out our latest analysis for Avecho Biotechnology
Our data indicates that Avecho Biotechnology Limited is worth AU$7.9m, and total annual CEO compensation was reported as AU$404k for the year to December 2018. We think total compensation is more important but we note that the CEO salary is lower, at AU$351k. We examined a group of similar sized companies, with market capitalizations of below AU$289m. The median CEO total compensation in that group is AU$379k.
So Ross Murdoch receives a similar amount to the median CEO pay, amongst the companies we looked at. This doesn't tell us a whole lot on its own, but looking at the performance of the actual business will give us useful context.
You can see a visual representation of the CEO compensation at Avecho Biotechnology, below.
ASX:AVE CEO Compensation, January 14th 2020
On average over the last three years, Avecho Biotechnology Limited has grown earnings per share (EPS) by 65% each year (using a line of best fit). It achieved revenue growth of 310% over the last year.
This shows that the company has improved itself over the last few years. Good news for shareholders. Most shareholders would be pleased to see strong revenue growth combined with EPS growth. This combo suggests a fast growing business. Although we don't have analyst forecasts shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.
With a three year total loss of 80%, Avecho Biotechnology Limited would certainly have some dissatisfied shareholders. This suggests it would be unwise for the company to pay the CEO too generously.
Ross Murdoch is paid around what is normal the leaders of comparable size companies.
We think that the EPS growth is very pleasing, but we find the returns over the last three years to be lacking. We'd be surprised if shareholders want to see a pay rise for the CEO, but we'd stop short of calling their pay too generous. CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Avecho Biotechnology (free visualization of insider trades).
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
If you spot an error that warrants correction, please contact the editor at email@example.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.
Go here to read the rest:
Should You Be Pleased About The CEO Pay At Avecho Biotechnology Limited's (ASX:AVE) - Yahoo Finance
Sofinnova Partners Announces the Promotion of Michael Krel to Partner of Industrial Biotechnology Team – Yahoo Finance
Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in Life Sciences, announced today the promotion of Michael Krel, PhD, to Partner of the Industrial Biotechnology team. Mr. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.
"This promotion recognizes Michaels excellent skills in the field of industrial biotech, and also reinforces the leading role that Sofinnova Partners is playing in this emerging sector," said Denis Lucquin, Managing Partner of Sofinnova Partners. "We look forward to working with Michael in his new role, and to the continued value his experience and deep subject area expertise bring to our pioneering work in this space."
Mr. Krel said, "It has been a privilege to serve the firm, and to help pioneer its development in Industrial Biotech. I look forward to continuing our work in this important area, and to the potential impact these investments will have globally."
Sofinnova Partners Industrial Biotech franchise is dedicated to start-ups with a specific emphasis on synthetic biology, food, feed, agriculture, materials and chemicals, and represents more than 200 M under management.
Mr. Krel joined Sofinnova Partners as a Senior Associate in 2013 and has been involved in the venture capital firms investment activities in industrial biotech since then. Mr. Krel is an observer on the board of Comet Bio and a board member of EnobraQ and Afyren.
Prior to joining Sofinnova Partners, Michael spent six years in industrial biotech start-ups, holding business development positions. Additionally, Michael was a consultant focused on R&D strategic and organizational issues.
Mr. Krel has a graduate degree in engineering from Ecole Polytechnique and holds a PhD in organic chemistry from Paris X Orsay University.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.
For more information, please visit: http://www.sofinnovapartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200114005847/en/
Press: Media: Kate BarretteRooneyPartners LLC+1 212 223 firstname.lastname@example.org
France Anne ReinS&I+33 6 03 35 92 email@example.com
The 30 rating InvestorsObserver gives to Intrexon Corp (XON) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 16 percent of stocks in the Biotechnology industry, XONs 30 overall rating means the stock scores better than 30 percent of all stocks.
Click Here to get the full Stock Score Report on Intrexon Corp (XON) Stock.
Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.
Intrexon Corp (XON) stock has fallen -5.84% while the S&P 500 is up 0.36% as of 11:35 AM on Wednesday, Jan 15. XON is down -$0.42 from the previous closing price of $7.19 on volume of 713,062 shares. Over the past year the S&P 500 is up 26.23% while XON is down -17.74%. XON lost -$3.58 per share the over the last 12 months.
To screen for more stocks like XON click here.
Global Biotechnology Reagents Market 2019-2023 | Evolving Opportunities with Agilent Technologies and BD | Technavio – Business Wire
LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global biotechnology reagents market since 2014 and the market is poised to grow by USD 37.98 billion during the period 2019-2023, progressing at a CAGR of almost 9% during the forecast period. Request free sample pages
Read the 136-page report with TOC on Biotechnology Reagents Market Analysis Report by Technology (Chromatography, In-vitro diagnostics, Polymerase chain reaction, Cell culture, and Others), Geography (Americas, APAC, and EMEA), and the Segment Forecasts, 2019-2023.
The market is driven by the high usage of biotechnology reagents in diagnostic and therapeutic applications. In addition, increasing stem cell and biomedical research is anticipated to boost the growth of the biotechnology reagents market.
The market is observing a significant rise in the demand for biotechnology reagents in diagnostic and therapeutic applications. This is due to advances in technologies such as cell structure, recombinant DNA and biotherapeutics, and emerging neurosciences and proteomics disciplines. The demand for ready-to-use reagents is also growing significantly in clinical laboratories and hospitals as they ensure minimal calculation, dilution, and pipetting errors. They also help reduce the duration of the diagnostic procedure and prevent sample contamination. These factors are crucial in driving the growth of the global biotechnology reagents market.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Biotechnology Reagents Market Companies:
Agilent Technologies operates the business through segments such as Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Erythrocyte-Lysing Reagent without Fixative, EasyLyse, Erythrocyte-Lysing Reagent, Uti-Lyse, and miRNA qPCR Detection Reagents.
BD operates the business through segments such as BD Medical, BD Life Sciences, and BD Interventional. The company offers a wide range of biotechnology reagents. BD OptiBuild, CD20 PE Clone L27 (ASR), and CD2 APC Clone L303.1 (also known as L303) (ASR) are some of its key offerings.
Bio-Rad Laboratories operates the business through segments such as life science, clinical diagnostics, and others. iScript RT-qPCR Sample Preparation Reagent, Kovacs Reagent, Anti-D Reference Reagent are some of its key offerings.
GENERAL ELECTRIC operates the business across various segments such as power, renewable energy, oil & gas, aviation, healthcare, transportation, lighting, and capital. The company offers a wide range of biotechnology reagents. Some of the key offerings of the company include Amersham ECL Detection Reagents, CDP-Star Detection Reagents, and PDEA Thiol Coupling Reagent.
Merck KGaA operates the business across segments such as healthcare, life science, and performance materials. The company offers a wide range of biotechnology reagents. Solvents for Liquid Chromatography LiChrosolv, Reagents for Acylation, and Silylation Derivatization Reagent are some of the key offerings of the company.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio's SUBSCRIPTION platform
Technavio has segmented the biotechnology reagents market based on the technology and region.
Biotechnology Reagents Technology Outlook (Revenue, USD Billion, 2019 - 2023)
Biotechnology Reagents Regional Outlook (Revenue, USD Billion, 2019 - 2023)
Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Healthcare include:
Global Affinity Chromatography Reagents Market Global affinity chromatography reagents market by end-users (pharmaceutical and biotechnology industry, food and beverage industry, cosmetic industry, and others) and geography (Asia, Europe, North America, and ROW).
Global Molecular Biology Enzymes, Kits, and Reagents Market Global molecular biology enzymes, kits, and reagents market by end-users (biotechnology and pharmaceutical companies, hospitals and diagnostic centers, and academic institutes and research organizations) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org
Adaptimmune Therapeutics plc and Japanese Astellas Pharma, Inc. have signed a discovery partnership to develop off-the-shelf allogeneic T cell-based cancer therapies from stem cells.
At J.P. Morgan conference, the British company announced that Astellas has agreed to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies against up to three targets. In contrast to current autologous T cell therapies, allogenic T cell therapies might be manufactured in a central facility reducing production cost significantly compared to autologous cell production and logistics.
Under the agreement, Adaptimmune will identify and validate new targets for generating target-specific T-cell receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that recognize surface epitopes independently from the HLA profile of the tumour cell. Astellas subsidiary Universal Cells, Inc will provide its Universal Donor Cell and Gene Editing Platform, which makes use of a stem cell-tropic rAAV vector for engineering humanpluripotent stem cells to contain deletions, insertions, or point mutations at any genomic position.
Adaptimmune has been collaborating with Universal Cells since 2015 on development of gene-edited induced pluripotent stem cell (iPSC) lines that generate proprietary T-cell products without the use of feeder layers.
Under the agreement, Astellas will fund research up until completion of a Phase I trial for each candidate with US$7.5m per year. Subsequently, Astellas and Adaptimmune may opt for co-development and co-commercialization of the candidate, or independent development through a milestone and royalty bearing licence. Under the agreement, Astellas will also have the right to select two targets and develop allogeneic cell therapy candidates on its own.
In case of Astellas would develop the candidates on its own, Adaptimmune may receive up to$897.5m in payments. If Adaptimmune would do so, Astellas may receive up to US$552.5m. If the companies opt for co-commercialisation any T-cell therapy, costs and profits will be shared equally.
ARTS WORK IN THE AGE OF BIOTECHNOLOGY: SHAPING OUR GENETIC FUTURES
Through Sunday, March 15
The Gregg Museum of Art & Design, Raleigh
Where do we draw the lines dividing art from science, natural from unnatural, and boldness from hubris?
An exhibit at N.C. States Gregg Museum of Art & Design doesnt answer these questions. Instead, it offers head-spinning new ways to ask them at the nexus of art and biotechnology, sharpening our insight into the fields future and expanding our understanding of it into the past.
These hard-to-classify collaborations between artists and scientistsseethe with hot-button issues related to ethics, privacy, human nature, and more. But if they have one message in common, its to be careful what you wish for.
Arts Work in the Age of Biotechnology: Shaping Our Genetic Futures is the result of more than two years of planning led by Molly Renda, the exhibit program librarian at N.C. State University Libraries, and the universitys Genetic Engineering and Society Center. Guest-curated by Hannah Star Rogers, who studies the intersection of art and science, the main exhibit at the Gregg has annexes in Hill and Hunt libraries.
On a recent tour of the exhibit, Renda and Fred Gould, the co-director of the GESC, said that they wanted to bring artists into the welter of science-and-design innovation taking place at the university because their differing perspectives on fundamental human issues create balance, tension, and discovery.
In the course of this, Ive found that artists tend to be more dystopian and designers are more utopian, Renda says.
There are different ways of knowing things, Gould adds. Thats why Molly came up with the name: not artwork, but arts work. What is an artist supposed to do?
Some pieces take on the dangers of day-after-tomorrow DNA testing and engineering technology. Heather Dewey-Hagborg is best known for Probably Chelsea, a piece in which she collected DNA samples from Chelsea Manning and generated thirty-two possible portraits of the soldier and activist.
When we worry about biotechnology, we usually worry that our food is going to be dangerous. But sometimes you wish for something thats rare: What happens when biotechnology makes it available to you?
The Gregg is showing a similar piece in which Dewey-Hagborg harvested DNA from cigarette butts and gum she found on the street and created probablebut not definitereplicas of the litterers faces, which hang on the walls above the specimens. Dewey-Hagborg demonstrates not only the unnerving extent of whats currently possible with DNA testing, but also the limits, which create misidentification risks.
Other pieces probe how biotechnology might reshape life as we know it. In a film and a sculpture representing an ancient Greek rite for women, Charlotte Jarvis raises the possibility of creating female sperm, based on the idea that, because stem cells are undifferentiated, you could theoretically teach womens stem cells to develop into sperm.
Still other pieces pointedly poke holes in the boundary between science and art. Adam Zaretskys Errorarium (entitled "Bipolar Flowers")looks like a cross between an arcade cabinet and a terrarium. It houses a few genetically modified Arabidopsis specimens, which Gould calls the white mice of research plants. When you turn the knobs, it changes the sonic parameters of a synthesizer, notionally testing the effects of the sound on the mutant plants.
It doesnt really do anythingor does it? Zaretskys experiment with no hypothesis is a playful tweak on science with something a little dangerous in the background.
Joe Davis, a bio-art pioneer, touches on something similar in his piece, which consists of documentation of an experiment where mice roll dice to determine if luck can be bred. Renda says that Davis couldnt get permission to run the test (universities are wary of drawing attention for ridiculous-seeming experiments), so he did it as conceptual art at N.C. State, instead.
Its notable that two artists home in on luck, one of many human concepts that genetic engineering, which will allow us to take control of our bodies and environment in untested ways, will transform. In We Make Our Own Luck Here, Ciara Redmond has bred four-leaf clovers (without genetic modification), which ruins themtheyrelucks evidence, not its cause. This whimsical iteration of unconsidered consequences raises a serious question: What else are we not thinking of?
When we worry about biotechnology, we usually worry that our food is going to be dangerous, Gould says. But sometimes you wish for something thats rare: What happens when biotechnology makes it available to you?
The exhibit takes an expansive view of biotechnology. Maria McKinney uses semen-extraction straws to sculpt proteins from double-muscled breeding bulls, underscoring that weve been tampering with life since long before CRISPR. Biotech feels radically new, but its revealed as part of a centuries-long process.
Another part of the exhibit, which closed at the end of October but can still be experienced through virtual reality at the Gregg, was From Teosinte to Tomorrow, Rendas land-art project at the North Carolina Museum of Art. In what was essentially a walk back through agricultural history, a bed of teosinte, which is thought to be the ancestor of modern maize, waited at the center of a corn maze.
That teosinte was in some sense genetically enhanced by subsistence farmers in Mexico since the time of the Aztecs, Gould says. Now were doing it in the laboratory with the same genesso whats the difference? Arts work is to make us think and question.
Contact arts and culture editor Brian Howe at email@example.com
Support independent local journalism.Join the INDY Press Clubto help us keep fearless watchdog reporting and essential arts and culture coverage viable in the Triangle.